Lisata Therapeutics (NASDAQ:LSTA) Trading Down 0.9% – What’s Next?

Lisata Therapeutics, Inc. (NASDAQ:LSTA)’s share price traded down 0.9% during mid-day trading on Thursday . The company traded as low as $3.30 and last traded at $3.33. 13,041 shares traded hands during trading, a decline of 83% from the average daily volume of 76,951 shares. The stock had previously closed at $3.36.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. HC Wainwright cut shares of Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. Zacks Research raised shares of Lisata Therapeutics to a “hold” rating in a report on Monday, May 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $15.00.

Lisata Therapeutics Stock Performance

The company has a market cap of $30.34 million, a PE ratio of -1.79 and a beta of 0.79. The company has a fifty day moving average of $3.33 and a two-hundred day moving average of $3.65.

Lisata Therapeutics (NASDAQ:LSTA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.50) EPS for the quarter. On average, equities analysts forecast that Lisata Therapeutics, Inc. will post -1.09 EPS for the current year.

Hedge Funds Weigh In On Lisata Therapeutics

Large investors have recently modified their holdings of the business. Renaissance Technologies LLC increased its position in shares of Lisata Therapeutics by 6.1% during the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock worth $230,000 after purchasing an additional 7,093 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new position in Lisata Therapeutics in the third quarter valued at about $37,000. Rangeley Capital LLC acquired a new position in Lisata Therapeutics in the first quarter valued at about $376,000. SOL Capital Management CO acquired a new position in Lisata Therapeutics in the first quarter valued at about $61,000. Finally, Cerity Partners LLC purchased a new position in Lisata Therapeutics during the second quarter worth about $32,000. Institutional investors and hedge funds own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.